Clozapine directly increases insulin and glucagon secretion from islets: Implications for impairment of glucose tolerance

[1]  P. Convertini,et al.  Insight into mechanism of in vitro insulin secretion increase induced by antipsychotic clozapine: Role of FOXA1 and mitochondrial citrate carrier , 2013, European Neuropsychopharmacology.

[2]  Jing-ping Zhao,et al.  Comparison of metabolic effects of ziprasidone versus olanzapine treatment in patients with first-episode schizophrenia , 2013, Psychopharmacology.

[3]  W. Honer,et al.  Intermittent treatment with olanzapine causes sensitization of the metabolic side-effects in rats , 2012, Neuropharmacology.

[4]  Min He,et al.  A continued saga of Boc5, the first non-peptidic glucagon-like peptide-1 receptor agonist with in vivo activities , 2012, Acta Pharmacologica Sinica.

[5]  G. Rewcastle,et al.  Effects of acutely inhibiting PI3K isoforms and mTOR on regulation of glucose metabolism in vivo , 2011, The Biochemical journal.

[6]  G. C. Smith,et al.  Olanzapine effects on body composition, food preference, glucose metabolism and insulin sensitivity in the rat , 2011, Archives of physiology and biochemistry.

[7]  W. Honer,et al.  Preclinical models of antipsychotic drug-induced metabolic side effects. , 2010, Trends in pharmacological sciences.

[8]  S. Obici,et al.  Central Nervous System Delivery of the Antipsychotic Olanzapine Induces Hepatic Insulin Resistance , 2010, Diabetes.

[9]  P. Shepherd,et al.  Clozapine and quetiapine acutely reduce glucagon-like peptide-1 production and increase glucagon release in obese rats: Implications for glucose metabolism and food choice behaviour , 2009, Schizophrenia Research.

[10]  G. Remington,et al.  Insulin resistance and secretion in vivo: Effects of different antipsychotics in an animal model , 2009, Schizophrenia Research.

[11]  S. Stahl,et al.  The metabolic syndrome and schizophrenia , 2009, Acta psychiatrica Scandinavica.

[12]  G. C. Smith,et al.  Atypical antipsychotic drugs induce derangements in glucose homeostasis by acutely increasing glucagon secretion and hepatic glucose output in the rat , 2008, Diabetologia.

[13]  Andrew A. Young,et al.  Boc5, a Non-Peptidic Glucagon-Like Peptide-1 Receptor Agonist, Invokes Sustained Glycemic Control and Weight Loss in Diabetic Mice , 2008, PloS one.

[14]  P. J. Larsen,et al.  The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance , 2008, Schizophrenia Research.

[15]  Henry A. Nasrallah,et al.  Schizophrenia, “Just the Facts” What we know in 2008. 2. Epidemiology and etiology , 2008, Schizophrenia Research.

[16]  JA Lieberman,et al.  Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway , 2008, Molecular Psychiatry.

[17]  T. Südhof,et al.  Impaired insulin secretion and glucose intolerance in synaptotagmin-7 null mutant mice , 2008, Proceedings of the National Academy of Sciences.

[18]  J. Thakore,et al.  Impaired glucose tolerance in first‐episode drug‐naïve patients with schizophrenia , 2007, Diabetic medicine : a journal of the British Diabetic Association.

[19]  K. Houseknecht,et al.  Acute Effects of Atypical Antipsychotics on Whole-Body Insulin Resistance in Rats: Implications for Adverse Metabolic Effects , 2007, Neuropsychopharmacology.

[20]  M. Iida,et al.  The atypical antipsychotic clozapine impairs insulin secretion by inhibiting glucose metabolism and distal steps in rat pancreatic islets , 2006, Diabetologia.

[21]  Anne W. Schmidt,et al.  Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perifused rat islets: role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemia. , 2005, Diabetes.

[22]  K. Melkersson.  Clozapine and olanzapine, but not conventional antipsychotics, increase insulin release in vitro , 2004, European Neuropsychopharmacology.

[23]  J. Thakore,et al.  Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. , 2003, The American journal of psychiatry.

[24]  A. Jablensky.  Prevalence and incidence of schizophrenia spectrum disorders: implications for prevention. , 2000, The Australian and New Zealand journal of psychiatry.

[25]  M. Roberts,et al.  An optimized model for rat liver perfusion studies. , 1996, The Journal of surgical research.

[26]  D. Schnur,et al.  FAMILY HISTORY OF TYPE 2 DIABETES IN SCHIZOPHRENIC PATIENTS , 1989, The Lancet.

[27]  G. Gores,et al.  The isolated perfused rat liver: Conceptual and practical considerations , 1986, Hepatology.

[28]  Valerie Beral,et al.  PREDICTIONS OF CERVICAL CANCER INCIDENCE AND MORTALITY IN ENGLAND AND WALES , 1986, The Lancet.

[29]  Pim W. Toonen,et al.  The role of hypothalamic pathways in the metabolic side effects of Olanzapine , 2013 .

[30]  Anneclaire J. De Roos,et al.  Epidemiology and Etiology , 2013 .

[31]  H. Pijl,et al.  Effects of olanzapine and haloperidol on the metabolic status of healthy men. , 2010, The Journal of clinical endocrinology and metabolism.